Ablynx expects that their Nanobodies might cross the blood–brain barrier and permeate into large solid tumours more easily than whole antibodies, which would allow for the development of drugs against brain cancers.
Ablynx espera que os seus nanocorpos poidan cruzar a barreira hematoencefálica e permear grandes tumores sólidos máis doadamente que os anticorpos completos, o cal permitiría o desenvolvemento de novos fármacos contra os cancros de cerebro.